Trial Profile
A clinical study of CAR-Treg in the prevention of chronic rejection after organ transplantation.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2018
Price :
$35
*
At a glance
- Drugs CAR Tregs-TxCell (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; First in man
- 24 Jan 2018 According to a TxCell media release, this trial is expected to initiate Q4 2018.
- 28 Jun 2017 New trial record
- 19 Jun 2017 According to a TxCell media release, this trial is expected to initiate by the end of 2018.